New technology will allow roadside simulation for research on cannabis use and driving

Video

Denise A. Valenti, OD, FAAO, gives key takeaways from her AAOpt 2022 discussion on the impact of marijuana use and driving.

Denise A. Valenti, OD, FAAO, CEO and owner of IMMAD (Impairment Measurement Marijuana and Driving), shares an update on her company's research during the 2022 American Academy of Optometry meeting held in San Diego.

Editor's note: This transcript has been edited for clarity.

Hi, I'm Dr. Denise Valenti. I am the owner of IMMAD (Impairment Measurement Marijuana and Driving), and I'm so pleased to be at this meeting. The Academy has recognized the importance of education for primary care clinicians and clinicians on cannabis.

I attended an incredible lecture by Dr. Ng from Southern California College of Optometry—a comprehensive lecture on basic information and cannabis. I'm excited to be presenting a lecture on driving and cannabis. This is in total conjunction with the area my company researches.

We are excited that we were recently awarded a grant from the federal government—the National Institutes on Justice—to measure a developing technology that looks at retinal function to determine if you're too high to drive.

Part of this project will be in developing a standardized, closed-road, real-car test system to detect impairment functions specific to driving. Now part of this is we're going to be working with a robotic technology that is very novel, we are going to be adapting the National Football League MVP practice dummy. We are turning it into a multi-directional robotic to use roadside as a simulation of our pedestrian.

So we are so excited that we have this opportunity to advance our research, but again, we're happy that the Academy recognizes how important it is for clinicians to know about cannabis/marijuana use and the impact on their patient.

Recent Videos
Optometrists reflect on their residency experiences and provide advice to current residents.
EnVision Summit Co-chairs Sherrol Reynolds, OD, FAAO; Katie Rachon, OD, FAAO, Dipl ABO; Jessica Steen, OD, FAAO, Dipl ABO; and Cecelia Koetting, OD, FAAO, Dipl ABO; express excitement for the upcoming conference and why optometrists should attend.
In 2 weeks, the study participant's dry eye symptoms improved from 76 to 43 on a 0-100 rating scale, according to Marc-Matthias Schulze, PhD, Dipl Ing.
Eye care practitioners reported moderate to high satisfaction with lifitegrast's ability to improve signs of dry eye, according to Melissa Barnett, OD, FAAO, FSLS.
Neda Gioia, OD, CNS, FOWNS, details the positive feedback gained so far from other optometrists that have been prescribing the NutriTears supplement to their dry eye patients.
Damaris Raymondi, OD, FAAO, highlighted the importance of building patient-doctor trust to learn about these practices, which can include non-traditional treatments like chamomile or manuka honey eye drops.
Noreen Shaikh, OD, Magdalena Stec, OD, FAAO, and Brenda Bohnsack, MD, PhD, emphasize that collaboration and communication are key to proper diagnosis and treatment.
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
Kerry Giedd, OD, MS, FAAO, was 1 of 20 investigators around the country for a study evaluating the daily disposable contact lens.
According to A. Paul Chous, MA, OD, FAAO, optometrists have an important opportunity to educate patients in their chairs about diabetes.
© 2024 MJH Life Sciences

All rights reserved.